| Sickle Cell Anemia |
1 |
1 |
| Stem Cell Research and Therapy |
0 |
0.93 |
| Biologic Therapy |
0 |
0.92 |
| Transplantation |
0 |
0.99 |
| Transplant Program |
0 |
0.52 |
| Match |
0 |
0.46 |
| Medical Life |
0 |
0.45 |
| Genomic Medicine |
0 |
0.37 |
| Gene Therapy |
0 |
0.34 |
| Graft |
0 |
0.28 |
| Toxicology |
0 |
0.18 |
| Cardiovascular Risk Management |
0 |
0.17 |
| Child |
0 |
0.17 |
| Renal Disease |
0 |
0.12 |
| Cerebrovascular Accident |
0 |
0.11 |
| Heart |
0 |
0.11 |
| Kidney |
0 |
0.11 |
| Lung |
0 |
0.11 |
| Patient Safety |
0 |
0.08 |
| Adverse Effects |
0 |
0.06 |
| Anemia |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Cancer |
0 |
0.06 |
| Cardiovascular disease |
0 |
0.06 |
| Chemotherapy |
0 |
0.06 |
| Face |
0 |
0.06 |
| Fertility |
0 |
0.06 |
| Food and Drug Administration (FDA) |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| I-Cell Disease |
0 |
0.06 |
| Immunocompromise |
0 |
0.06 |
| Lysosomal Storage Disease |
0 |
0.06 |
| New York |
0 |
0.06 |
| Psychosocial |
0 |
0.06 |
| Tennessee |
0 |
0.06 |